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1.  Introduction  
The following chapter presents a general overview of the research question. Background and 
problem discussion shed light on the main issues highlighted in the further chapters.  
1.1 Background 
A fast changing business environment caused by a transformation of technology, 
communications and business itself, has created a new landscape for many industries during the 
last few decades. In today’s business milieu, being innovative doesn’t mean being competitive 
any more (Chesbrough, 2007). Companies invest more and more in the development of new 
products and technologies, but benefit less and less from that. Besides, products’ lifecycle is 
becoming shorter and shorter which means that innovation itself doesn’t guarantee long-term 
profitability (Chesbrough, 2007). In addition to that, the convergence of technologies resulted 
into a shift of boundaries between industries. For example, 10 years ago education, entertainment 
and the communication market were serviced by different actors and products, but nowadays it is 
embedded into one product (Prahalad and Ramaswamy, 2003). This indicates even greater 
uncertainty – rules established for different industries are blurring now. Creating product variety 
has become easier, but competition for value through product variety has become tougher. The 
above factors make companies rethink the way they do their business. 
 
The most convenient and recent way to illustrate how the company builds its business (that is 
how the company creates value for itself and the customer) is through the business model. The 
business model has become more important than innovation today – one technology 
commercialized in two different ways will give two different outcomes (Chesbrough, 2010). 
Business models are even subject to patent law, like Amazon.com has a patent for one-click 
purchase (Rappa, 2002). Due to the novelty of the concept there is no unified definition of the 
business model, though it has become a part of the vocabulary of every manager (Shafer, Smith 
and Linder, 2005). For the purpose of this study definition suggested by Chesbrough & 
Rosenbloom (2002) will be used: 
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“Business model is a framework that takes technological characteristics and potentials of the 
company as inputs, and converts them through customers and markets into economic 
outputs.” 
 
Projecting the definition into practice, it is important to understand that a business model implies 
a system of interdependent elements which make the enterprise function towards a certain 
strategic direction. The problem with defining units of a business model remains the same: 
scholars haven’t come to the single conclusion about the structure of business models. Most 
perspectives on business models imply a company’s offering and a set of activities necessary to 
produce and deliver that offering to the market (Morris et al., 2005). The definition of offering 
implies a specific product or service which a company offers to customers at the market. 
Structural decomposition of the business model into interrelated units differs among the scholars 
dependently on the prevailing theoretical framework. Cross-theoretical origins of the business 
model concept lie in the value chain concept (Porter, 1985), the resource-based theory (Barney et 
al., 2001), the strategic network theory (Jarillo, 1995), the cooperative strategy (Dyer and Singh, 
1998) etc. Therefore, some authors define a business model’s elements in a more strategic 
context (Hamel, 2001; Weil and Vitale, 2001 etc), whereas some scholars make stronger 
emphasizes on a firm’s available capabilities (Betz, 2002; Chesbrough and Rosenbaum, 2000 
etc).  
 
With the purpose of determining a company’s business model, Osterwalder (2004) proposed to 
use nine interdependent elements (key partners, key activities, key resources, value proposition, 
customer relations, channels, customer segments, cost revenue and revenue streams) organized 
into four pillars (value proposition, customer interface, infrastructure management and financial 
pillar). The business model was later developed by Osterwalder and Pigneur (2009) into a 
business model canvas, which is “a strategic management tool, a visual template preformatted 
with the nine blocks of the business model, which allows to sketch out new or existing business 
models”. The business model canvas has a wide practical implication among practitioners and 
allows illustrating the basic business model of any enterprise. The business model developed by 
Osterwalder (2004) and its practical visualization (business model canvas) developed by 
Osterwalder and Pigneur (2009) will be used in this paper.  
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Projecting the business model canvas concept  (Osterwalder and Pigneur, 2009) on the definition 
of the business model suggested by Chesbrough and Rosenbloom (2002), a modified definition 
of business model is synthesized for the purpose of this paper: 
 
“Business model is a framework that takes company’s technological characteristics and 
potentials built on key activities, key resources and key partners as inputs and converts them 
through target customer segments, customer relations and markets as a distribution channel 
into economic outputs by means of value proposition (product or service offering) creation 
and delivery”. 
 
Companies should understand their business model to mark out incentives for its development, 
interdependencies with other actors and weaknesses – so that they know when and how they 
need to make a shift in their business to remain successful and growing (Johnson et al., 2008). 
Coming back to the changes which are dominating in the business landscape today, many 
industries have faced the necessity of rebuilding its current business models with the purpose of 
staying competitive: oil industry in late 1970’s, automotive in mid-1980’s, electronics in late 
80’s, chemicals/specialties in early 1990’s and personal care in mid-1990’s (Chitra, n.d.). An 
interesting case is the pharmaceutical industry today - being reshaped with new challenges and 
proving the main business trends, it faces the need to acquire new rules for the new business 
arena.  
 
Pharmaceutical industry, according to Britannica Encyclopedia (2009), comprises “public and 
private organizations involved in the discovery, development, and manufacture of drugs and 
medications”. Traditionally, the business model in the pharmaceutical industry is built around the 
“blockbuster drugs” targeted at the mass market. Generally accepted definition of the 
blockbuster drug is based on the revenue size from the drug sales which exceeds $ 1 billion. 
Moreover, blockbuster drugs comprise about one third of the pharmaceutical market sales 
revenue (Seget, 2010). IMS report (2011) estimated global pharmaceutical market in 2010 in 
$850 billion. Moreover, Seget (2010) is forecasting the growth of the global pharmaceutical 
market to $1,033 billion in 2014. 
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Nowadays the pharmaceutical industry faces complex challenges which make pharmaceutical 
companies to rethink the way of doing business. From one side, technological progress, 
emerging markets and demographical factors open new opportunities for the pharmaceutical 
industry. From other side, licenses expiry for blockbuster drugs and generics’ expansion (generic 
drug is a drug product that is comparable to brand/reference listed drug), economic limitations 
and regulation restrictions put pressure on the market (Mercer commentary, 2001). 
 
Following the main business trends, one of the major problems in the pharmaceutical industry is 
lack of productivity. A future uncertainty has become the main challenge for the pharmaceutical 
industry and put the existing pharmaceutical business model, which was dominating at the 
market for a long time, under the risk. The blockbuster business model
1
 nowadays gives returns 
on investments lower than industry’s adjusted cost of capital (Gilbert et al., 2003). 
Pharmaceutical companies have to move from the blockbuster and fully integrated business 
model to alternative ones. Strategically, the business model shift should be aimed at more 
efficient cost management, customer/value management and a defragmented business model 
(Chitra, n.d.). Defragmented business model is a business model focused on the specific part of 
the production pipeline. 
 
Focused on the pharmaceutical industry, current study covers the main challenges and trends in 
the pharmaceutical industry in relation to the business model concept and reveals how 
pharmaceutical companies cope with market shifts and challenges with the help of business 
modeling. 
1.2 Problem discussion 
The pharmaceutical industry today is facing so called “productivity paradox” – companies invest 
more money in research and development, but the number of medicines approved is lessening. 
The Business model which has been prevailing in the industry – the blockbuster model - implied 
                                                 
 
1 For the purpose of this study, blockbuster business model – business model built around the production and distribution of the blockbuster drug 
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fully integrated architecture of pharmaceutical companies. That means that the whole value chain 
is locked inside the company. At the final stage only a small number of drugs achieve global 
sales (in this case sales usually exceeds 1 billion) resulting in large profits (Chitra, n.d.). The 
major risk the blockbuster model faces is the great uncertainty concerning the success of the drug 
development at the final stage. The return on investment must be higher than the cost of capital 
to make the firms able to gain profit. Thus the revenues from the blockbuster sales should cover 
investment for research and development, drug manufacturing, drug delivery to the market and 
other costs. 
There are several major trends which are shifting the pharmaceutical industry today: 
 Value creation can’t be generated through company-centric, product-and-service prism 
any more (Prahalad and Ramaswamy, 2003). Since the range of the products at the 
market became overwhelmed, customers are seeking not only for quality and variety, but 
for the best solutions. Ability to discover, test, manufacture, and distribute highly valued, 
complex products doesn’t ensure value creation (Mercer commentary, 2001). Nowadays 
patients are becoming more informed – they are looking not only better medicines, but 
also a range of satellite services (PriceWaterHouseCooper report, 2009). 
 
 Investors are shifting their market valuations to business units which focus on satisfying 
critical customer priorities (Mercer commentary, 2001).Value migration is moving from 
the fully integrated pharmaceutical companies to the defragmented companies which 
specialize on particular parts of the value chain pipeline. 
 
 The shift from a closed business model to an open business models can be observed. 
Since companies are finding it more difficult to justify investments in innovation - 
development costs are rising because of rising costs of innovation and market revenue is 
lessening because of the shorter product life cycle in the market. This pushes companies 
to open their business models in order to get new revenues and cut development costs 
through leveraging external development (Chesbrough, 2007). 
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 Networking. Companies are joining networks for realizing joint business projects. 
Partnership networks give companies a possibility to strengthen their competitive 
advantage and to maximize the profits through acquiring resources and capacities it 
doesn’t have. In addition to that, partnership networks are a great basis for sharing 
knowledge, experience and risks. 
 
 With the rise of new technologies, communication services and digitalization the 
boundaries between industries are blurring. For the pharmaceutical industry it means 
that the established distribution pipeline, which is used to go from the laboratory to the 
pharmacy, is not working any more. Pharmaceutical companies should establish a strong 
network between educational institutions, public services and customers to be able to 
have sustainable growth. 
 
As a result of the trends mentioned above, the old business models are not efficient for 
pharmaceutical companies any more. Companies should reshape the way of doing business to 
stay competitive and to sustain growth. 
  
1.3. Purpose and research question 
The purpose of the following study is to clarify the major shifts in the business models in the 
pharmaceutical industry due to the changes in the business environment and industry itself. The 
theoretical framework of the study implies the use of the business canvas concept for illustrating 
the business architecture of pharmaceutical companies. Therefore, the paper is focusing on the 
firm-level analyses.  
 
Research question of the following paper concerns the importance of the shift in the business 
models in pharmaceutical industry. The paper is seeking to answer the following questions: 
- What is the old business model in pharmaceutical industry? 
- What is the new business model in pharmaceutical industry? 
- What are the major difference between old blockbuster business model and new alternative 
model? 
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- What is the shift in business models in pharmaceutical industry in the recent decades? 
This study adds to the literature on business models in pharmaceutical industry and sheds light 
on the importance of the shift in business models for the pharmaceutical companies. The purpose 
of the empirical part based on the qualitative research is to give a deeper insight into the 
alternative new business models in the pharmaceutical industry.  
 
1.4. Thesis outline 
The following study focuses on two major blocks of issues: the business model concept and the 
pharmaceutical industry`s development. The first part of the paper is devoted to the theoretical 
framework and modeling. The Introductory chapter gives an overview of the theoretical 
framework used for the further research, as well as presents a problem discussion and research 
questions of the paper. The second chapter presents the literature review and the theoretical 
framework. Also the discussion about the business model and business model canvas concepts 
are further presented. Two theoretical models (the old blockbuster and the alternative 
defragmented business models) for pharmaceutical companies are constructed and compared. 
  
The third chapter of this paper sheds light on the pharmaceutical industry by highlighting the 
major trends and shifts which occurred during the recent few decades. The empirical part 
(chapters four and five) is devoted to an in-depth study of the pharmaceutical companies in 
Skåne region, Sweden. The business models of two pharmaceutical companies are built based on 
the theoretical framework and compared with theoretical projections of old blockbuster and 
alternative defragmented models. The last chapter covers discussion and conclusions. 
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2.  Literature review and theoretical framework 
The following chapter presents a discussion on the business model concept among various 
practitioners and scholars. The definition of the business model is synthesized on the basis of 
analysis of different theoretical approaches and the business model used for the further research 
is specified and explained. The final section of the chapter is devoted to the theoretical 
discussion about the business model’s elements and their detailed explanation.  
2.1. Business model concept 
Though the term “business model” has become an inevitable part of managers’ and scholars’ 
vocabulary, there is still no generally accepted definition for it. Differences in definition cause 
challenges and often misunderstandings about the structural nature, its components and the 
functions of the business model. The absence of a unified definition also causes confusion in 
terminology – the term “business model” is often mixed with such terms as strategy, revenue 
model, economic model etc. (Morris et al., 2005). Moreover, as a result of theoretical and 
standard ambiguity in definition and, relatively, in general understanding, there is a confusion in 
practical implication of the business model concept (Shafer et al., 2005). 
 
A business strategy and business model are often used as a similar terms. The roots of such 
confusion lie in the absence of an agreed definition of both terms.  
 
A business model is not a strategy itself, but it determines and reflects the company’s strategic 
choices and their operating implications. A properly identified business model can be a great 
strategic tool for the company (Shafer et al., 2005). Using business model as a canvas describing 
how company operates in a business environment gives that company a possibility to react 
quickly to the changes which continuously occur in the business landscape. Business modeling 
also helps company to analyze its place at the market and to see new possibilities for growth and 
development as well as for maintaining a competitive advantage. 
 
The research made by Osterwalder et al. (2005) indicates that the term “business model” became 
extremely popular only 2 decades ago. Existing business model literature usually concentrates on 
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one of the two blocks of issues: either the product, business actor and network aspects (Afuah 
and Tucci 2001; Chesbrough and Rosenbloom, 2000) or marketing specific aspects (Weill and 
Vitale, 2001; Magretta, 2002; Petrovich et al., 2001).  
 
Another distinction between different authors is in their way of presenting business model 
concept – some of them only provide a definition and some of them try to decompose a business 
model into smaller interrelated elements. The deconstruction of the business model is crucial for 
understanding of the incentives and patterns of business model’s functioning and giving it 
practical meaning. Similarly to the definition, there is no common structure of the business 
model among scholars. Table 2.1 presents a summary of the definitions and business model 
components defined by different authors. Since the deconstruction of  business model into 
elements is the only useful tool for business planning which helps to describe and understand 
business logic of the firm, authors who attempted to design both – definition and decomposition 
of business model - are considered in this paper. 
 
Authors 
 
Definition Components 
Afuah and Tucci 
(2001; 2003)  
Activities that allow a firm to make 
money in a sustainable way 
Customer value, scope, pricing, revenue 
source, connected activities, 
implementation, capabilities, sustainability 
Amit and Zott 
(2001) 
Architectural configuration of the 
components of transactions designed to 
exploit business 
opportunities 
Novelty, lock-in, complementarities and 
efficiency 
Chesbrough and 
Rosenbloom 
(2000) 
Framework that takes technological 
characteristics and potentials of the 
company as inputs, and converts them 
through customers and markets into 
economic outputs 
Value proposition, market segment, value 
chain, competitive strategy, value network, 
cost structure and profit potential 
Johnson, 
Christensen and 
Kagermann 
(2008) 
Composition of 4 interlocking elements 
which, taken together, create and 
deliver value 
Customer value proposition, profit 
formula, key resources and key processes 
Magretta (2002) Story that explains how enterprise 
works 
Two elementary parts: business activities 
associated with making something (e.g. 
design, procurement, and manufacturing) 
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Table 2.1. Definition and components of the business model by authors 
Scholars often describe business model through abstract categories which makes it difficult to 
capture the precise meaning and importance of the business model. For example, Magretta 
(2002) defines business model as a story that explains how enterprise works. Following the same 
line of explanation, Afuah and Tucci (2001) present business model as a set of activities that 
allow a firm to make money in sustainable way. Petrovic and Kittl (2001) explain business 
model as the logic of a business system for creating value. Though these explanations are 
reasonable in their general meaning, their practical implication is questionable because of lack of 
precision and clarity. 
 
A more accurate explanation and definition of the business model is presented by Weill and 
Vitale (2001) through the description of the roles and relationships among consumers, customers, 
allies and suppliers which identifies the major flows of product, information and money, as well 
as the major benefits for participants. Following the product-centric approach, Osterwalder et al. 
and business activities associated with 
selling something (e.g. customer 
identification, selling, transaction 
handling, distribution and delivery) 
Osterwalder et al. 
(2005) 
Description of the value a company 
offers and, at the same time, a 
description of the architecture of this 
company and its network for creating, 
marketing, and delivering this value 
with the purpose to generate profitable 
and sustainable revenue streams 
9 building blocks: value proposition, key 
activities, key resources, partner network, 
cost structure, client relationship, client 
segments, distribution channels and 
revenue flows 
Petrovic, Kittl et 
al. (2001) 
Logic of a business system for creating 
value 
Seven sub-models, which are the value 
model, the resource model, the production 
model, the customer relations model, the 
revenue model, the capital model and the 
market model 
Weill and Vitale 
(2001) 
Description of roles and relationships 
among consumers, customers, allies 
and suppliers and it identifies the major 
flows of product, information and 
money, as well as the major benefits for 
participants 
Strategic Objective and Value Proposition, 
Sources of Revenue, Critical Success 
Factors, Core Competencies 
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(2005) presents a business model as a description of the value which company offers and, at the 
same time, description of the architecture of this company and its network for creating, 
marketing, and delivering this value with the purpose to generate profitable and sustainable 
revenue streams.  
 
Amit and Zott (2001) suggest that business model is an architectural configuration of the four 
major components (novelty, lock-in, complementarities and efficiency) which are constructed for 
the discovery and utilization of business opportunities. Similarly, Johnson at al. (2008) are 
building their concept around the business model which implies a composition of four 
interlocking elements (customer value proposition, profit formula, key resources and key 
processes) which create and deliver value in interaction with each other.  
 
For the purpose of the following paper definition suggested by Chesbrough & Rosenbloom 
(2002) is used:  
 
“A Business model is a framework that takes technological characteristics and potentials of 
the company as inputs, and converts them through customers and markets into economic 
outputs.”  
 
The above definition provides a coherent and complex understanding of the meaning of business 
model. Since this definition goes in line with the business model concept suggested by 
Osterwalder (2004), it will be further modified for the purpose of this research. 
 
Confusion about the business model components is resulting from the lack of clarity and unified 
structure leads to limitations in practical implication of the concept. Thus, while Magretta (2002) 
configure only two elements of business model – business activities associated with making 
something and business activities associated with selling something, Chesbrough and 
Rosenbloom (2002) decompose business model into six parameters - value proposition, market 
segment, value chain, competitive strategy, value network, cost structure and profit potential. 
The choice of the business model architecture in this case should be driven by criteria of 
simplicity and perspicuity of the elements included. The above presented business model’s 
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deconstructions are suffering from the limited practical implication: simplicity of Magretta’s 
(2002) approach doesn’t allow to present the whole picture of the company’s business structure, 
while the approach suggested by Chesbrough and Rosenbloom (2002) is lacking structural clarity 
for business modeling. 
 
Weill and Vitale (2001) define strategic objectives and value preposition, source of revenue, 
critical success factors and core competencies as major building blocks of the business model. 
Similarly, Johnson et al. (2008) point out four interlocking elements that create and deliver value 
together: customer value proposition, profit formula, key resources and key processes. Afuah and 
Tucci (2001) completed value proposition, revenue source, connected activities and capabilities 
with such elements as scope, pricing, implementation and sustainability. Though the structural 
elements presented by the authors above are more clearly defined, there is a lack of practical 
explanation of those elements for detailed business modeling.  
 
Similar approach but different categorization has been used by Petrovic and Kittl (2001) who 
deconstructed business model into seven sub-models: value model, the resource model, the 
production model, the customer relations model, the revenue model, the capital model and the 
market model. 
 
In contrast to the business concepts presented above, Osterwalder et al. (2004) made the most 
detailed and practical description of the business model’s structure presenting business model as 
a description of the value which company offers and, at the same time, description of the 
architecture of this company and its network for creating, marketing, and delivering this value 
with the purpose to generate profitable and sustainable revenue streams. The business model 
suggested by Osterwalder (2004) was further transformed by Osterwalder and Pigneur (2009) 
into the business models canvas – a managerial tool for business model construction.  
Since the concept suggested by Osterwalder (2004) presents the most comprehensive and 
detailed view of the company’s business model and suggests convenient practical tool for 
business modeling (business model canvas), it is used in the paper as a major theoretical 
framework.   
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2.2. Business model specification: final definition and concept 
Osterwalder (2004) points out four business model pillars which contain nine building blocks 
(Figure 2.1).  
 
 
Figure 2.1. Business model by Osterwalder (2004) 
 
A central pillar in the model is value proposition – it contains the overall view of the company’s 
bundle of products and services and answers on the question “WHAT does the company offer?”  
 
The second pillar, built on three business blocks (key activities, key resources and key partners), 
contains information about infrastructural management and answers the question “HOW does 
the company do that?”. Key partners outline a partnership network needed for offering and the 
commercializing of the value proposition (e.g. outsourcing). Thus key partners influence a set of 
key activities company performs for execution of the actual business model. Similarly, there is a 
link between partnership network and key resources of the company – business networks help 
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companies to outsource those capabilities which are not of a core importance for them and to 
strengthen those capabilities, which give competitive advantage to the company. Key partners 
and key resources blocks determine the cost structure of the company which is part of the 
finance pillar.  
 
The infrastructure management pillar together with the cost structure block determines and 
deliver value proposition to the target customers. Key partners outline a partnership network 
needed for offering and the commercializing of the value proposition (e.g. outsourcing). Thus 
key partners influence a set of key activities company performs for execution of the actual 
business model. Similarly, there is a link between partnership network and key resources of the 
company – business networks help companies to outsource those capabilities which are not of a 
core importance for them and to strengthen those capabilities, which give competitive advantage 
to the company. Key partners and key resources blocks determine the cost structure of the 
company which is part of the finance pillar. The infrastructure management pillar together with 
the cost structure block determines and deliver value proposition to the target customers. 
 
The customer pillar is answering the question “WHO will consume our offer?” and consist of 
three blocks: customer relationships, customer segments and distribution channel. Value 
preposition itself is a predominant factor for customer segment (target customer) establishment, 
customer relationship (links between the company and different customer segments) 
maintenance and distribution channel (various means a company uses to reach the customers) 
implementation. The second part of the finance pillar, revenue stream, depends on the customer 
segment block (if the target customer consume the company’s offer, it will raise revenue 
streams). A revenue stream, in turn, influence value proposition itself (Osterwalder, 2004). 
 
This simple model covers the all major components needed for the business model description 
and projection. The business model concept developed by Osterwalder (2004) suffers from the 
lack of practical implication in the definition of the business model itself. For this reason, 
definition suggested by Chesbrough & Rosenbloom (2002) can be modified within 
Osterwalder’s (2009) concept: 
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“A business model is a framework that takes a company’s technological characteristics and 
potentials built on key activities, key resources and key partners as inputs and converts them 
through target customer segments, customer relations and markets as a distribution channel 
into economic outputs by means of value proposition (product or service offering) creation 
and delivery”. 
 
On the basis of business model developed by Osterwalder (2004), Osterwalder and Pigneur 
(2009) presented business model canvas. Business model canvas (Osterwalder and Pigneur, 
2009) is a practical template based on the theoretical business model (Osterwalder, 2009). As it 
is illustrated on the Figure 2.2, business model canvas consists of the same elements as presented 
above model by Osterwalder (2004) (Figure 2.1).  
 
Figure 2.2. Business model canvas by Osterwalder and Pigneur (2009) 
Variety of business model’s formulations doesn’t guarantee practical applicability of all those 
models. As a result of interactions between globalization and increasingly rapid technological 
development, it has become harder for managers to make a choice concerning their value 
proposition, value network, partners and the ways to reach the customer etc. (Archibugi and 
Iammarino, 2002). 
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The theoretical framework of the business model concept is only useful for the companies if they 
can understand it and project it onto reality – thus the managers will managers understand what 
their business is and how should they execute it. For that reason Osterwalder and Pigneur (2009) 
suggested that company should visualize their business model by using business model canvas. 
 
Building company’s business model requires clear understanding of each business model’s pillar 
– so that the manager can use is as a strong analytical tool for visualization of his/her business 
model. The following subsections provide detailed description about the four pillars of the 
business model suggested by Osterwalder (2004): value proposition, customer interface (which 
consists of the three blocks: customer relations, distribution channel and customer segment), 
infrastructure management (which consists of three blocks: partnership network, key resources 
and key activities) and financial aspects (which consists of two blocks: cost structure and 
revenue streams). 
2.2.1. Value proposition 
 
As it is illustrated on the Figures 2.1 and 2.2, value proposition is a central pillar in the business 
model. The all other pillars are either involved into creation of this value proposition, or into its 
delivery to the customers for the final purpose of getting revenues. 
 
Osterwalder (2004) suggested that value proposition and its offerings should be analyzed in the 
light of the following attributes: reasoning, life cycle, value level and price level. Table 2.2 
summarizes meaning and classification of each attribute. 
 
 
Attribute Explanation Classification 
Reasoning Why the firm thinks its value preposition or a 
specific elementary offering could be valuable 
to the customer 
How is value created: 
- use; 
- risk; 
- effort. 
Value level 
(customer utility) 
Measuring the utility for the customer by 
measuring the value level of a company's offer 
allows a firm to compare itself to its 
competitors 
Measure: 
- me-too value; 
- innovative imitation; 
- excellence; 
- innovation. 
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Price level The comparison of the value proposition's 
price level with the one's of their competitors 
Scale: 
- free; 
- economy; 
- market; 
- high-end 
Life Cycle Capturing at which stage of the value life cycle 
an elementary offering creates value 
Stages of the value life cycle: 
- customization; 
- purchase; 
- use; 
- renewal; 
- transfer 
Table 2.2. Attributes of value proposition and its elementary offerings. Source: 
Osterwalder (2004) 
In the business model suggested by Osterwalder (2004) value proposition covers all aspects 
which company offers to its customers: products, services or their combination, as well as 
product differentiation from competitors. Value proposition, delivered to the customers through a 
bundle of products and services consist of elementary offering(s) (Osterwalder, 2004). Being a 
part of value proposition, elementary offering stands for each specific product or service which 
company offers to the customer and represents the value which this offering deliver to that 
customer. A Company can better understand its position in the market by decomposing value 
preposition into elementary offerings and comparing them to competitors.  
 
Each value proposition can create value for the customer in a different ways: through usage of 
the product (painkillers); reduction of the customer’s risk (insurance offering); making 
customer’s life easier through reduction of his efforts (hands free set). Designing new value 
proposition company should think about the reasons for becoming this specific offering valuable 
for the customer.  
 
A comparative analysis of the company’s product competitiveness can be done by customer 
utility evaluation. The value level of the offering starts with me-too value, when the company 
offers similar to the wide range of products proposition. Innovative imitation brings higher value 
to the customer through a reduced price for innovative elements added to existing products. 
Value can be also delivered to the customer through excellence: exclusive service or product 
offering for a high price. Innovation delivers value to the customers through offering new 
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products or services which can better satisfy customers’ needs. Innovation places a high-end 
position in the value level evaluation scale because companies gain competitive advantage at the 
market through incomparable products and services (until the innovation is imitated) (Linder and 
Cantrell, 2000). 
 
The price level of the offering can be measured according to the simple scale: from free and 
economy level to market and high-end level. A company’s offering can also create value on 
different stages of a proposition’s life cycle: at the moment of value creation itself 
(customization), at the moment of purchase (one-click shopping at Amazon), use (watching a 
movie), renewal (software updates) or transfer (selling of used things) (Osterwalder, 2004). 
 
Value proposition, e.g. the product which companies offer to the customer is one of the core 
elements of the business model. Today’s conditions at the market put companies in a difficult 
situation. From one side, such trends as globalization, emerging new technologies and shortening 
of the products’ life cycle transformed traditional markets into rapidly changing arena for 
competition, where the boundaries between industries started to disappear. From another side, 
the emergence of active, informed and hyper-connected consumers changed prerequisites for 
products’ demand and criteria for customers’ choice of the product. It is easier to create a 
product variety today, but it is becoming harder to compete for value through product variety 
(Prahalad and Ramaswamy, 2003). Companies increasingly organize in networks creating a 
bundle of products or services which are offered together as a customer solution which has a 
higher value than the product itself. 
 Changes at the market, shaping the business landscape, make companies to rethink their value 
preposition and even entire business model (Osterwalder, 2004). Those companies who are able 
to innovate and transform value preposition quickly according to the customer’s needs and rapid 
market changes are becoming market leaders nowadays (Kim and Mauborgne, 1997). 
 
Simple analysis of value proposition according to the four above described attributes is a helpful 
tool for the company to position its offering at the market, to point out its strength and 
advantages in comparison with competitors, as well as to figure out possible places of 
improvement or space for new product or services implementation.  
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2.2.2. Customer interface 
 
According to Osterwalder’s (2004; 2009), the customer interface pillar covers everything which 
is related to the customer. The three blocks included into the customer interface are target 
customers, which build different customer segments; channels, through which value is 
distributed and delivered to target customers; and relations between customers and companies. 
Table 4 presents a summary of the elements included into each block of the customer interface 
pillar. 
Business model block Explanation Components 
Customer segments Target customers - B2B customers 
- B2C customers 
Channels Distribution and delivery of the 
value proposition 
- Direct 
- Indirect 
Customer relations Relations between the company 
and target customer 
Ways of supporting relations: 
- Acquisition 
- Retention 
- Add-on selling 
Mechanisms: 
- Personalization 
- Trust 
- Brand 
Table 2.3. Customer interface blocks. Source: Osterwalder, 2004 
Segmentation of target customers is of core importance for the company’s business strategy. 
Precisely specified group of customers helps the company to make a good allocation of its 
resources – so that the offering will deliver value to those customers who are really interested in 
it.  
 
Distribution channel consists of different links between the company and customer. This 
business block describes how the company delivers value to the customers. The major shift in 
distribution channels’ configuration today is caused by progressive development of information 
and communication technologies (ICT) – more and more distribution channels are shifting to the 
ICT space (on-line shops, e-commerce, m-commerce). Besides, some changes occurred in the 
structure of distribution channel itself. While traditional channel links two actors – supplier and 
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customer, there are more and more intermediaries appearing which place themselves in between 
those two actors. One of such intermediaries is a platform, which brings together groups of users 
in two-sided networks. Blockbuster products and services which dominated at the market for a 
long time link together two types of users in the network – suppliers and customers.  
 
Customer relations’ block contains data on relations established between the company and its 
customers. Clearly defined customer segments to which company address its value proposition 
should be continuously supported and communicated by different mechanisms. The strategy of 
the company on whether to focus on acquisition of new customers from specified segment,  
retention of old customers or add-on selling to existing customers should be guided by the type 
of value offering as well as by customer segment specificity. The defined strategy of customer 
relations can be implemented through different mechanisms.  
 
Personalization as a mechanism of customer relations stands for several things. First, it stands for 
personalized relations with the customer – learning his/her buying habits and product 
preferences, maintaining dedicated personal assistance etc. In this case one-to-one marketing 
relationship stands on the first place. Second, personalization stands for one-to-many relationship 
– from company to a group of customers with the certain needs (Osterwalder, 2004). Besides, 
each customer can participate in value creation through collaborative community. An advantage 
of this mechanism is not only in having an active feedback from the customer, but in the 
customer’s participation in the process of value proposition creation, i.e. customer’s direct 
involvement into the product improvement, e.g. through on-line communities (Gloor and 
Cooper, 2007). 
 
Trust has become another important issue in customer relations – sustaining trust between the 
company and the customers by different means (guarantees, risk reduction mechanism) is a 
prerequisite for long-term relations between them. Another important mechanism of customer 
relations is branding. The value of the brand is not limited with a mechanism of customer 
relations support – it also constitutes a part of competitive advantage of the value proposition. A 
brand is influenced by every interaction with the customer and it absorbs new customers from 
the same segment by automatically generated trust (in case of positive branding). 
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Designing of the customer interface is a helpful tool for the company to visualize its target 
customers’ segment, as well as the ways of supporting and communicating with it.  
2.2.3. Infrastructure management 
 
According to Osterwalder (2004), the infrastructure management pillar describes how company 
creates value and consists of three interrelated blocks: core capabilities (key resources), value 
configuration (key activities) and partnership networks (key partners). These three business 
blocks contain information about the abilities of the company to provide value proposition to the 
target customers and abilities to support relations with those customers. The infrastructure 
management pillar specifies a company’s main activities to execute business, its in-house core 
capabilities and those acquired through a partnership network. 
 
The core capability block is based on the set of resources possessed by the company. These 
resources can be classified into tangible, intangible and human resources (Osterwalder, 2004). 
Tangible resources include plants, equipment and cash reserves; intangible resources cover 
intellectual capital (patents, copyrights, brands) reputation and trade secrets; human resources 
include people who create value with the help of tangible and intangible resources.  
It is of strategic importance for a company to define its core competence and to build a 
competitive advantage on it. The shift that can be noticed today is that successful companies 
open their business models and outsource those capabilities which are not core for them. Rising 
costs of innovation together with shorter product life cycle in the market result in that companies 
with closed business models loose their profitability. The companies with open business models 
are able to get new revenues from out-licensing, spinoffs and sales and save cost and time from 
leveraging external development (Chesbrough, 2007). 
 
Wallin (2000) categorizes resources among two axes – internal-external and customer-resources, 
and points out four types of company’s capabilities: resource-integration, generative, customer-
interaction, and transformative capabilities, as it shown in the Figure 2.3.  
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Figure 2.3. Capabilities according to Wallin (2000) 
Resource-integration capabilities cover a company’s ability to deploy its assets and capabilities 
inside (internal integration) and outside (external integration) the company. The generative 
capabilities include those core in-house capabilities necessary for the creation of the value 
proposition. This can be done either through innovation (R&D) or through execution 
(production). The customer-interaction capabilities include abilities necessary for customer 
relations’ maintenance. The transformative capabilities “refers to the ability to combine bundles 
of product traits that in terms of physical, service, and people content have the threshold traits 
required by each customer and which can be offered at costs less than their perceived value 
creating potential.” (Wallin, 2000). 
 
The value configuration consists of key activities the company executes to create value 
proposition on the basis of available resources (either owned or partners´ resources), as well as 
links between those activities. All the necessary activities are performed either by the company 
itself or by its partners. The partnership network visualizes resources and those parts of value 
configuration which are distributed among a company’s partners. In general terms, a partnership 
is a voluntary agreement between several business entities to carry out a joint project through 
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coordination of common resources, capabilities and activities (Osterwalder, 2004). Nowadays 
companies participate in business networks with the aim to increase their competitive advantage 
– a collaboration strategy helps companies to acquire capabilities they don’t have internally and 
combines resources of several units if the business project implementation requires that 
(Wolthuis, 2010). In addition to that, partnership networks help companies to maintain 
optimization and economy of scale, as well as to reduce the risks and uncertainty (Osterwalder, 
2004). 
 
Osterwalder (2004) pointed out the following incentives for companies to participate in business 
networks: 
 Partnership for customer acquisition; 
 Partnership to acquire knowledge (building of knowledge webs (Eneroth, 2001); 
 Partnership to share risks in developing new markets (Prahalad and Hammond, 
2002); 
 Partnership for financial outsourcing. 
 
Key resources, key activities and key partners determine a company’s competitive advantage 
and, thus, possibilities for sustainable growth and development. A company’s strategy should be 
focused on building the best possible configuration of available resources and activities within 
the business network for the creation of competitive value proposition. 
2.2.4. Financial aspects 
 
According to Osterwalder (2004), the financial aspects’ pillar covers the revenue model and cost 
structure and is an outcome of the configuration of other business model’s blocks. The revenue 
streams and cost structure explain company’s profit and loss-making strategy. In other words, the 
financial pillar defines how company creates value for itself through creation and delivering 
value to the customers (Johnson et al., 2008). 
 
Osterwalder (2004) points out two elements of the revenue streams block – revenue stream itself 
and pricing. Dependently on the value proposition, a company’s business model can include one 
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to several revenue streams (each offering can have its own revenue stream) with different pricing 
mechanisms. The different stream types and pricing mechanisms are shown in the table 2.4. 
 
The different revenue streams are based on the kind of value proposition and the way company 
monetizes it. The monetization of the value proposition can be maintained through different 
ways: through selling the product or service; through lending the product (leasing, bank loans 
etc); licensing or franchising; transaction cut (fee for using matchmaking facilities for suppliers 
and buyers); advertising. The pricing mechanisms can be divided into three main groups: fixed 
pricing, differential pricing and market pricing dependently on characteristics which determines 
the pricing process.  
 
Market pricing is dependent on the real-time market conditions and includes bargaining between 
buyers and sellers for the price; yield management (maximizing profits from perishable assets); 
auction and reverse auction (which has become extremely popular with the rise of the internet); 
dynamic market (when the price is dictated by the market conditions). Differential pricing 
doesn’t depend on real-market conditions – the major factors which determine the price in this 
case are volume, consumer (or product) characteristic, or customer preferences. 
 
Differential pricing can be product feature dependent (the price of the product or service is 
determined by the features included in it); customer characteristic dependent (knowing the 
customer behavior allows to put the price for the product or service according to the customer’s 
characteristics); volume dependent (the price is dependent on the volume of product purchased 
by the customer); value based (dependent on how much the customer is ready to pay for the 
value delivered with the product or service). Finally, fixed pricing is not dependent on any of the 
above mentioned factors. Fixed pricing include pay-per use (customer pay per every unit of used 
production or service); subscription (customer pays a flat fee); menu pricing (fixed price with is 
set in the catalogue).  
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Pricing mechanism Description Type 
Fixed pricing  Do not differentiate in function of 
customer characteristics; 
 Volume independent; 
 Are not based on real-time market 
conditions. 
Pay-per use 
Subscription 
List price/menu price 
Differential pricing  Are not based on real-time market 
conditions; 
 Either volume dependent; 
 Or based on consumer or product 
characteristic; 
 Or linked to customer preferences. 
Product feature dependent 
Customer characteristic 
dependent 
Volume dependent 
Value based 
Market pricing  Based on real-time market conditions. Bargaining 
Yield management 
Auction 
Reverse auction 
Dynamic market 
Table 2.4. Pricing mechanisms. Source: Osterwalder, 2004  
 
The cost structure block includes the all costs spent by the company for creation, marketing and 
delivering value to the customer. According to Osterwalder (2004), the cost structure together 
with the value proposition determines whether the company is value-driven or cost-driven. A 
value-driven company focuses on the delivery of the high qualified products and services – that 
is why they don’t concentrate on the cost reduction strategy. In opposite, cost-driven companies 
are trying to reduce costs for value proposition creation and make their products or services more 
accessible through a lower price.  
 
Analysis of all the building blocks of a company’s business model illustrates the way this 
company functions and makes money. Together with rapidly changing market analysis, the 
business model construction is a perfect tool of identification of strong and weak places in 
company’s strategy for sustainable growth. The theoretical framework described above will be 
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used in the further research for analyses of the shifts in business models in pharmaceutical 
industry in recent decades. 
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3. Pharmaceutical industry overview: challenges and perspectives.  
The following chapter presents an overview of the global pharmaceutical industry, its major 
trends and challenges. Two business models – the old blockbuster business model and the 
alternative defragmented business model are conceptualized on the basis of the theoretical 
framework highlighted in the previous chapter. 
3.1. Overview of the pharmaceutical industry  
The pharmaceutical industry is characterized by the risky and lengthy R&D process, severe 
competition for intellectual property, restrictive governmental regulations and strong purchase 
pressures (Bátiz-Lazo and Holland, 2001). Though all mentioned features put high pressure on 
the companies operating in the pharmaceutical industry, the size of the pharmaceutical market is 
growing. According to Seget (2010), the global pharmaceutical market grew to $808 billion in 
2009, at a compound annual growth rate of 9.3% between 1999 and 2009 which indicates quite 
high industry growth. Seget (2010) estimated the global pharmaceutical industry to grow to 
1,033 billion in 2014. 
 
Traditionally, the business model of the pharmaceutical companies has been built around the 
blockbuster drugs, which supposed to bring high sales revenues. According to Seget (2010), the 
existing top 100 blockbuster drugs have already generated sales of US$285 billion. There are 
around 125 blockbuster drugs in total generated more than $1billion each in global sales. To 
exemplify, one of the top blockbuster drugs is Lipitor – cholesterol-lowering medication 
produced by Pfizer with sales US$ 13,28 billion in 2009 and US$12,6 billion in 2010 (IMS 
report, 2011). Table 3.1 illustrates the sales volume of the top five blockbuster drugs in 2009 and 
2010. Table 3.2 and Graph 3.1 present the biggest pharmaceutical companies in terms of sales in 
2010. 
 
No Brand Company 2009 Sales 
(US $ BN) 
2010 Sales 
(US $ BN) 
1.  Lipitor Pfizer, Astellas 13.28 12.66 
2.  Plavix Bristol Myers Squibb, Sanofi Aventis 9.1 8.82 
3.  Remicade J&J, Merck, Mitsubishi Tanabe 5.4 6.04 
4.  Advair Glaxo Smith Kline 8.09 8.47 
5.  Enbrel Amgen, Pfizer, Takeda 5.8 6.17 
Table 3.1. Top five blockbuster drugs. Source: IMS Health Midas, December 2010 
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 Graph 3.1. Top 10 Global pharmaceutical corporations, 2010, Total Audited Markets. 
Source: IMS Health Midas, December 2010  
 
Rank 
(2010) 
Company 2010 Sales  
(US $ MN) 
2009 Sales  
(US $ MN) 
2011, Fortune 500 
revenue (US $ MN), / 
Fortune 500 rank 
6.  Pfizer (US) 55,602 57,024 67,809 / 31 
7.  Novartis (Swiss) 46,806 38,460 - 
8.  Merck & Co (US) 38,468 38,963 45,987 / 53 
9.  Sanofi-Aventis 35,875 35,524 - 
10.  AstraZeneca (UK/Sweden) 35,535 34,434 - 
11.  GlaxoSmithKline (UK) 33,664 34,973 - 
12.  Roche 32,693 32,763 - 
13.  Johnson&Johnson (US) 26,773 26,783 61,587 / 40 
14.  Abbott (US) 23,833 19,840 35,166 / 69 
15.  Eli Lilly and Company (US) 22,113 20,310 23,076 / 115 
 
Table 3.2. Top 10 Global pharmaceutical corporations, 2010, Total Audited Markets. 
Source: IMS Health Midas, December 2010  
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Nowadays the biggest challenge for the blockbuster companies is patent expiries of the branded 
drugs (blockbusters) and high proliferation of generic drugs. According to the Center for Drug 
Evaluation and Research (n.d.), generic drugs are "drug products comparable to brand/reference 
listed drug products in a dosage form, strength, route of administration, quality, performance 
characteristics, and intended use”. According to the IMS report (2011), the market share for 
blockbuster drugs fell from 70% in 2005 to 64% in 2010 and is expected to drop to 53% in 2015. 
The Datamonitor report (2010) states that blockbuster patent expiries in 2010 have led to erosion 
of $78 billion in global branded sales of drugs. From the customers’ perspective, patent expiries 
will save payers $120 billion by 2015 compensated by $22 billion of generic drugs (IMS report, 
2011).  
 
Chitra (n.d.) denoted that one of the major challenges for pharmaceutical companies is 
uncertainty – making huge investments in the development of new drugs, including all phases of 
development process, doesn’t mean that the company will succeed bringing the drugs to the 
market.. Increasing spending on R&D results in a decreasing number of drugs approved and 
commercialized – so called “productivity paradox” has become typical for the pharmaceutical 
industry. For the fully integrated blockbuster pharmaceutical company
2
, which contains the 
whole process of the drug development and commercialization, such uncertainty can have 
dramatic outcomes – the return on investment (ROI) is lower than the industry’s risk adjusted 
cost of capital. Gilbert et al. (2003) pointed out four major reasons for reduction in expected ROI 
from the launch of the new drugs: 
 Shorter exclusivity periods; 
 Declining R&D productivity; 
 Rising costs of commercialization; 
 Increasing payor influence. 
 
                                                 
 
2 For the purpose of this study, blockbuster (pharmaceutical) company – pharmaceutical company with blockbuster business model 
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To a large extend, shorter exclusivity periods can be explained by emergence of generic drugs. 
The length of the drug`s development process is longer than the period of drug’s exclusivity at 
the market – generic drugs are coming into the competition and, due to the lower price, acquire 
bigger market share.  
 
The productivity paradox in the pharmaceutical industry is a consequence of the high costs and 
lengthy development time of launching new drugs to the market, strengthened with growing 
regulatory and economic pressure (Litinski, 2010). As a result, revenue growth with decreasing 
margins has become typical for the pharmaceutical industry today (PriceWaterHouseCooper`s 
report, 2009). To overcome this challenge, pharmaceutical companies should focus their R&D 
efforts on a specific segment – either on a specific customers segment or on specific kind of 
medicines. Another important issue for pharmaceutical companies is the shift towards 
partnership – from a “profit alone” path to a “profit together” path (PriceWaterHouseCooper`s 
report, 2009). Partnership networks help companies to reduce the risk and volatility, and help to 
concentrate on the firms competitive advantages. Companies should outsource capabilities which 
are not core for the activities they execute (for example administration or manufacturing) 
(Gilbert et al, 2003). As Chitra (n.d.) noticed, pharmaceutical companies should leverage their 
value chain and recapture value by focusing on particular parts of the value chain. Focusing on 
core activities in combination with out-sourcing and in-sourcing will help companies to improve 
their R&D productivity and to mitigate risks. 
 
Rising costs of commercialization is a result of a rigid supply chain in the pharmaceutical 
industry. According to PriceWaterHouseCooper`s report (2009), an increasing emphasis on 
outcomes which covers the expansion of the pharmaceutical industry to the health management 
service, leaner cost structure with diminishing margin growth, as well as a new structure of 
health care delivery are pushing pharmaceutical companies towards fragmentation and closer 
cooperation with their customers.  
 
Increasing payor influence can reveal in several ways. On the one side, it is based on the highly-
informed customers, who want not only better medicines, but also satellite services with it 
(PriceWaterHouseCooper`s report, 2009). On the other side, pay-for-performance strategy 
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among the payors is becoming more popular. Customers are willing to pay for the outcomes. In 
addition to that, customers tend to shift their demand from the science driven therapeutics to 
customer solutions with the drug in the center (Gilbert et al, 2003).  
 
Therefore, the blockbuster business model will not foster sustainable growth to the 
pharmaceutical companies in the future. Next generation of blockbuster medicines are likely to 
emerge from companies with a more specialized – defragmented - business model (Gilbert et al, 
2003). Those pharmaceutical companies which are shifting to a diversified business models 
(with modular structure) with clear focus on activities based on the companies’ available core 
capabilities, will be able to support sustainable long-term growth. 
 
Two theoretically built business models will be conceptualized and compared in the further 
research – blockbuster business model and defragmented business model. 
3.2. Blockbuster and defragmented business models in pharmaceutical 
industry: theoretical comparison 
As it is illustrated in the Figures 3.2 and 3.3, the blockbuster business model has some significant 
differences from the alternative disintegrated business model. To start with, the first element in 
pharmaceutical business model, which is under attack, is its value proposition. The single 
offering which the blockbuster pharmaceutical company is striving to deliver to the market is a 
new blockbuster drug. The above offering creates value for the customer through usage of 
invented drug and is delivered through drug innovation. The price level of blockbuster drugs 
usually starts from the high end after the drug launch, but it comes down to the market price 
soon. The given offering creates value on the “use” stage of the proposition’s life cycle. The 
blockbuster company’s value proposition is both value- and cost-driven. From the one side, 
blockbuster pharmaceutical companies create drugs aimed at quality and innovation, but from 
the other – these drugs are aimed to gather revenues from high sale volumes among different 
customer segments. The main challenge for the pharmaceutical companies with value 
proposition block is short exclusivity period and competition with generic drugs. When patent 
protection for the blockbuster drug expires, generic drug immediately substitutes that drug at a 
lower price. As a result, generics are acquiring large market shares and blockbuster companies 
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are losing their revenues. Life licensing or out-licensed manufacturing can be a solution to that 
problem. 
 
In comparison with the blockbuster model, the variety of value propositions in the defragmented 
model is much wider, because defragmented model focuses on particular part of the product 
pipeline. Recent trends show a movement towards including satellite services into the real 
product proposition: for example diagnostics (Osterwalder, 2005). All the attributes of the value 
proposition in a defragmented business model depend on the offering. For example, if a 
pharmaceutical company specializes on contract drug manufacturing, it will create value by 
effort reduction; deliver it through me-too value, innovative imitation or innovation (dependently 
on the manufacturing process); at a market price. 
 
A customer segment and distribution channel blocks are the next in the queue to become a weak 
place in the blockbuster business model. The value proposition in the blockbuster model is aimed 
at the wide range of customers at the mass market – there is no clearly defined customer segment 
(target customers cover patients and doctors without any specifications). In contrast, the 
defragmented business model targets its value proposition at a niche market. It can be either a 
group of patients with a specific disease (diabetes); pharmaceutical companies which outsource 
drug development of special kind of medicines on early/late stages of development; 
pharmaceutical companies which outsource drug manufacturing etc. Concentration on niche 
markets together with delivering either cost-effective or high-quality value proposition will allow 
pharmaceutical companies to maintain certain customer segments through retention and, if 
necessary, add-on selling. While the blockbuster pharmaceutical companies are forced to spend 
more money on their blockbuster drug marketing than on the R&D of new medicines, the 
defragmented pharmaceutical companies can invest saved on promotion costs into the key 
activities. The blockbuster business model requires big advertising campaigns for their products 
which are quite costly and it excludes the possibility of personalized relationships with the 
customers. Acquired through advertisement customers are maintained mainly with branding 
mechanism. In contrast, a defragmented model is aimed at more personalized relations with 
customers, which gives company a possibility to have an active feedback and to participate in 
collaboration process with them for improving the quality of the value proposition. 
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Infrastructure management in the blockbuster business model has one distinction feature which 
determines all further structure of its building blocks – the all-in-house production. A 
blockbuster company keeps the whole production pipeline inside independently on its core 
capabilities. Furthermore, such pharmaceutical companies don’t participate in any business 
networks, which increase uncertainty level and company’s expenses on activities which are not 
key to its value proposition (it can be high costs of manufacturing, marketing or financial 
management inside the company). 
 
The key resources of blockbuster company include generative capabilities (both - innovation and 
production) and internal integration capabilities. The key activities are built on the basis of these 
locked in the company resources – the blockbuster company maintains the production chain 
together with internal management. The defragmented model is focused on its core capabilities, 
e.g. capabilities on which a company can build a competitive advantage. In contrast with the 
blockbuster model, the defragmented model outsources those capabilities which are not core and 
insource those capabilities which are needed for value proposition delivery. Besides, the 
defragmented model reduces risks and uncertainty through participation in the business 
networks. Networking helps companies to acquire customers and to share knowledge for 
improving value proposition. The organization of the infrastructure pillar determines the 
structure of the financial pillar of these two models. 
 
The biggest disadvantage of the blockbuster business model is the high risk of uncertainty – 
companies are making huge investments in new drug discovery and development without any 
risk diversification. Uncertainty in this case concerns the blockbuster drug launch at the market – 
there are no guarantees that the new drug development process will be successful and that it will 
be introduced to the market. As a result, the level of investments (mainly in research and 
development) of the new drugs often exceeds the cash flows in a later stadium from those drugs 
(ROI is lower than the companies cost of capital). 
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Figure 3.2. Blockbuster business model of the pharmaceutical company (conceptualized on the basis of business model concept by 
Osterwalder (2004) and business model canvas by Osterwalder and Pigneur (2009) 
Offer Infrastructure Customer 
Finance 
No partner networks 
 
Generative 
capabilities: 
innovation and 
production; internal 
integration capabilities 
 
 
All-in-house: 
R&D (phases 1-4 of 
drug development); 
clinical testing, 
manufacturing, 
distribution and 
marketing, internal 
management 
 
Supporting relations 
through acquisition; 
Mechanism: brand, 
trust 
 
Direct – either through 
own pharmacies or 
regular pharmacies; 
Mass markets 
B2C customers: 
Patients; Doctors; 
 
 
Offer: blockbuster drug; 
Reasoning: use; 
Value level: innovation; 
Price level: market or high-end; 
Life cycle: use 
 
R&D costs; drug discovery development process; marketing; management  
 
Stream type: licensing; selling; 
Pricing mechanisms: product feature dependent; 
Cost/value driven 
Partner network Key activities 
Key Resources 
Value proposition Customer 
Relationship 
 
Distribution Channel 
Customer Segments 
Cost Structure Revenue Stream 
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Figure 3.3. Defragmented business model of the pharmaceutical company (conceptualized on the basis of business model concept by 
Osterwalder (2004) and business model canvas by Osterwalder and Pigneur (2009)
Offer Infrastructure Customer 
Finance 
Partnership for 
customer acquisition, 
acquiring knowledge, 
sharing risks in 
developing markets 
and outsourcing 
Clearly defined core 
capabilities 
 
 
Activities based on 
core capabilities 
 
Supporting relations and 
Mechanisms: 
dependently on the 
customer segment  
 
Dependently on the 
customer segment 
Either B2C or B2B 
customers: target 
segments should be 
clearly specified for 
each offering – niche 
markets 
 
Offering is based on the particular 
part of the drug development 
pipeline (R&D; drug development 
on the phases 1-2; drug 
manufacturing etc) 
Reasoning, Value level, Price level 
and life cycle are dependent on the 
offer; 
 
 
Costs related to the core capabilities utilization  
 
Dependently on the value proposition and key activities 
Partner network Key activities 
Key Resources 
Value proposition Customer  
Relationship 
Distribution Channel 
Customer Segments 
Cost Structure Revenue Stream 
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The cost structure of the blockbuster business model includes expenses on R&D, drug 
manufacturing, marketing and internal management of the company. The revenue stream comes 
mainly from the high volumes of blockbuster drug sales and, sometimes, from licensing. Since 
the defragmented business model is focus-oriented, its cost structure is related to its core 
capabilities utilization. The revenue streams, respectively, are based on the core activities and 
kind of value proposition. For example, the revenue streams in the defragmented business model 
can come from the drug manufacturing if the company focus on contract drug manufacturing. 
The cost structure in this case will include fixed and variable production costs (considering 
economy of scale).  
 
The two theoretical models illustrate how the changes in business environment shifted the way of 
running business nowadays. The obsolete blockbuster model is not efficient any more – smaller 
specialized pharmaceutical companies are becoming more competitive at the market. 
 
The following chapter presents the analysis of business models in the pharmaceutical industry 
based on the several in-depth interviews with pharmaceutical companies in the Skåne region in 
Sweden. The business models of these companies are conceptualized on the basis of 
Oswerwalder’s (2004) business model and Osterwalder and Pigneur (2009) business model 
canvas concept, and compared with theoretical business models constructed in this chapter. 
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4. Methodology 
The following chapter presents the methods used for the empirical research. In-depth interview 
approach is described and discussed in terms of its limitations and advantages for the following 
study. 
 
Previous sections of the research presented a theoretical analysis of the business model concept 
in the context of general changes in the business environment and, in particular, in the 
pharmaceutical industry. The two business models representing the pharmaceutical industry were 
constructed according to the theoretical framework presented in Chapter 2. The aim of the 
further empirical research is to give a deeper insight into the business models in the 
pharmaceutical industry on the example of the two pharmaceutical companies in Skåne region, 
Sweden. In-depth interview studies of the two pharmaceutical companies were held for the 
purpose of the following empirical research. On the basis of the obtained data the business 
models of these companies were constructed and compared with the theoretical blockbuster 
model presented in the previous chapter.  
 
The choice of in-depth interviewing for the empirical research was guided by the data 
specification needed for the business model construction. Since business modeling requires 
detailed and profound information about the company, in-depth interviewing is the only method 
capable to provide it. The major limitation of all other data collection methods in comparison 
with in-depth interview, is that they are structured (e.g. surveys), which makes it possible to 
obtained only narrowly specified set of information. In contrast, in-depth interviews enable to 
explore compound problems and to receive additional information and clarifications about the 
researched issue (Berg, 2009; Denzin & Lincoln, 2000). 
 
Under the ideal circumstances, three pharmaceutical companies: two pharmaceutical companies 
with the similar profile (size, age, location) and one blockbuster company would have been 
interviewed. Data for the business model construction on the two pharmaceutical companies 
(Camurus AB and QPharma) is easy to compare and, besides, similarity in companies’ profiles 
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allow to point out distinctive features between their business models. The interview with the 
blockbuster company would have helped to get a deeper insight into the company’s business 
model, as its theoretical projection is used for the analysis. At least three one-to-one personalized 
interviews should have been conducted with companies’ CEOs: general introductory interview, 
more specific interview and final interview aimed at details’ clarification.  
 
Under the given circumstances two pharmaceutical companies - Camurus AB (Lund, Sweden) 
and QPharma (Malmö, Sweden) - were interviewed. The selection of the companies was made 
on the basis of their availability and willingness to participate in the in-depth interviews. Hence, 
the common feature of the companies is location (Skåne, Sweden: Lund and Malmö). This factor 
cannot be considered as limitation, since it hasn’t influenced the results of the research – it only 
gave a slightly different direction for the empirical analysis in terms of its structure. Due to the 
time restrictions, the data collection was held in three stages for each company: available 
information research (instead of the first general interview); one 1-hour specific in-depth 
interview with the company’s CEO; e-mailing for the details clarification (instead of the final 
interview).  
 
In addition, one in-depth interview with the Business Development Manager of the Swedish 
investment agency responsible for supporting the life science companies in Skåne region (“Invest 
in Skåne”) was held for the purpose of data collection on the general patterns of the 
pharmaceutical industry in the region. “Invest in Skåne” is a Swedish part of Medicon Valley - 
one of the most famous life science clusters situated in the eastern Denmark and south-western 
Sweden. 
 
For the purpose of coherency and validity of the results, the all interviewees were presented in 
the theoretical framework of the business model canvas by Osterwalder and Pigneur (2009) used 
for business model construction. The guidance for the interviews contained three groups of 
guiding questions. The first group contained several general questions - interviewees were asked 
about their view of the pharmaceutical industry: 
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“Which major trends and challenges do you see in pharmaceutical industry today?”; “What are 
the major shifts of the pharmaceutical industry happened during the last 15-20 years?”; “How 
can you describe your business model?”; etc. 
 
Second group contained guiding questions about company’s business model. The all questions 
were aimed at obtaining maximum information about each block of the company’s business 
model: 
 
“How can you describe your value proposition?”; “What are the core competences necessary to 
execute your business model?”; “How does your company generate revenue?”; etc. 
 
The general evaluation questions were presented to the interviewees in the last group: 
 
“How can you evaluate your business model?”; “What are the major challenges for your 
business model?”; “How can you overcome them?”; “What is your strategy for the future 
growth?”; etc. 
 
The data recording was made by a voice recorder and the interviewer’s notes. All the recorded 
interviews were further transformed into the typed transcript.  
 
The data analyses was organized in a few steps. First, the all information was divided in different 
categories: general questions, specific questions and personal questions (which highlight 
interviewees’ point of view). Specific information on the companies’ business models was 
projected on the theoretical framework: the data collected from the companies was analyzed and 
structured according to the business model concept by Osterwalder and Pigneur (2004). As a 
result, two business models were constructed and compared with the theoretical model presented 
in the previous chapter. 
 
On the basis of the experience gained during the empirical study mentioned above, few 
considerations should be bared in mind for the further research. First, general one-to-one 
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interview might be important in terms of information and reflections of the interviewees. This 
first flow of information can give unexpected turn for the further discussion and to give new 
ideas for the researcher. Second, the final personalized interview might be important in terms of 
detailed discussion and clarification of the already by researcher analyzed issues. To conclude, in 
case of in-depth interviews personalized meetings are more valuable than other ways of 
communication in terms of data collection.  
 
The major limitation of the following empirical research is lack of standardization. Since the in-
depth interviewing strategy covers only few companies, it cannot be generalized on the whole 
pharmaceutical industry in the region. Therefore this empirical study doesn’t attempt to make 
any generalizations on the basis of its findings. 
 
The following empirical research with in-depth interviews gives a deep insight into the complex 
issue of the shift in business models in the pharmaceutical industry and is a solid basis for the 
further research in this sphere. 
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5. Empirical data 
The following chapter presents the descriptive data analysis collected during the empirical 
research. First, the pharmaceutical industry in the Skåne region is presented based on the 
interview with Life Science Business Development Manager of “Invest in Skåne”. Second, the 
pharmaceutical companies Camurus AB and QPharma are introduced and discussed. 
5.1. The pharmaceutical industry in Skåne 
Skåne region in Sweden is a part of the biggest life science clusters in Europe called Medicon 
Valley.  Established in mid-90’s, Medicon Valley covers the Öresund region where life science 
has been developing and growing as an industry for a long time. Though the population of the 
Öresund region is only 3,5 million people in total, collaboration inside the cluster comprises 
around 450 companies mainly focused on R&D, universities and hospitals. The Swedish part of 
Medicon Valley - Invest in Skåne - is a state agency responsible for attraction of investments to 
the region (Medicon Valley, 2011).  
 
The life science industry in the region includes pharmaceutical, biotechnological and medtech 
industries (Invest in Skåne, 2011). According to Life Science Business Development Manager 
Anna Cherouvrier Hansson, the majority of the life science companies in Skåne region, in 
contrast with Denmark, are small companies – often incubating companies - with innovative 
products. A big proportion of the companies is still in developing phase without any products at 
the market. IDEON science village in Lund is a contributing factor for the growth of small 
companies.  
 
Skåne region has a great potential for the development of the pharmaceutical industry. There are 
several big pharmaceutical companies (McNeil AB in Hesingborg, QPharma in Malmö, Astra 
Zeneca (now it moved to Denmark, but it influenced the development of the region a lot), 
Recipharm AB in Jordbro etc) and many small biotech companies which provide projects - 
mainly R&D - for the big pharma. As Anna Cherouvrier Hansson mentions: 
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“It’s a general trend – concentrating on the main areas and outsourcing R&D to smaller 
companies. For these smaller companies the main issue is to find a big pharmaceutical company 
as a partner. For example, the contract between Swedish research-based pharmaceutical 
companies developing innovative antibody drugs BioInvent AB and biotech company Genetech 
in the USA is based on Genetech’s investments in BioInvent’s antibodies development (it’s on the 
phase II). In return, Genetech will receive the rights to launch the product in the USA.” 
 
The main shift in the pharmaceutical industry during the last 10-15 years is risk aversion. The 
big pharmaceutical companies are willing to produce new blockbusters (which are antibodies and 
biological compounds), but at the same time they want to reduce the risk. Therefore, big 
companies invest in smaller biotech companies. Making an agreement on what results should be 
achieved at each stage of development, the big pharmaceutical companies can break the 
collaboration if expected results are not met. The risk and losses in such case are lower than in 
case of the whole unit’s closure inside the company. As CEO of Camurus AB Fredrik Tiberg 
denotes: 
 
“For example, after seven years of development process you want to start selling something 
within the diabetes. You build up the structure and when it comes to registration – you are 
refused. It’s a slow process of development with very abrupt failures. The challenge is to create a 
buffer which gives you consistency. If a small company fails with only one product which they 
have – the company is gone. For the big companies it can be USD 20 billions’ loss in one night – 
a very rapid change in a very slowly developing industry.  
 
Before, companies were very risk taken. Now companies are shifting to the option deals (license, 
acquire) when there is a smaller amount of cash which is driving you to the next step (risk 
aversion). For small companies – earlier the option field was bigger, now it’s smaller and 
payments don’t come until the level of risk is minimized.” 
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Two companies chosen for this research present their perspective on the way they conduct 
business in the pharmaceutical industry in Skåne region. Table 5.1 presents main characteristics 
of the companies which participated in the following case study. 
 
Characteristic Camurus AB QPharma 
Location Lund, Sweden Malmö, Sweden 
Year of establishment 1991 1999 on the basis of Ferring 
Size (number of 
employees) 
27 (+ contractors) 115 
Type of the company Drug delivery company Contract manufacturing company 
Key activities Drug-delivery technologies; 
R&D: 5 in-house projects 
(preclinical phase – ready 
projects), 2 out-licensed 
projects, range of partner 
projects  
Contract drug manufacturing; 
contract drug development; 
analytical services 
Interviewed person CEO CEO 
 
Table 5.1. Main characteristics of the pharmaceutical companies  
(Camurus AB, 2011; QPharma, 2011) 
 
5.2. Camurus AB 
Camurus AB is a drug delivery company. Situated in Ideon Science Village in Lund, it 
specializes in drug delivery technologies (oral nanoparticles, injection depot, injection 
nanoparticles, topical bioadhesive and transdermal nanoparticles). Beside of the drug delivery 
technologies, the company has several in-house R&D projects, out-licensed projects and partner 
projects, as it shown in the Table 5.2. 
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Activity Name of the product Phase of 
development 
In-house/out-
licensed/partner 
project 
Drug-delivery 
technologies 
FluidCrystal
®
 NP Oral 
nanoparticles 
Registered In-house 
FluidCrystal
®
 Injection depot 
FluidCrystal
®
 NP Injection 
nanoparticles 
FluidCrystal
®
  Topical 
bioadhesive; 
FluidCrystal
®
 NP Transdermal 
nanoparticles 
R&D CAM 2036 (diabetes part  II) Preclinical  
 
CAM 2038 (drug addiction, pain) Phase I 
CAM 2029 (acromegaly, cancer) Phase II 
CAM 2032 (prostate cancer) 
Episil - CAM 2028 (oral 
mucositis),  
Registered 
Elyzol dental gel (Parodontitis) Out-licensed 
Salinum® Xerostomia (dry 
mouth) 
Undisclosed products, oncology, 
anesthesia, metabolic disease, 
pain (multiple partners ) 
Preclinical Partner 
Table 5.2. Value proposition structure at Camurus AB.(Camurus AB, 2011) 
CEO of the company described the business model of Camurus AB as following: 
“We are looking for the new customer’s needs in terms of therapeutic functionality (modality) to 
develop and exit at phase II or III or even take it through all the way to registration and then 
Tetyana Syrovatka                                                              MSc in Economic growth, innovation and spatial dynamics 
48 
 
exit. Development to the certain suitable exit point depends on how much investments do we have 
to make up to phase II or III, or till registration. 
 
Identification of our customers’ needs is a dual process. From one side, we have our certain 
functional spectrum of technology. From the other side, we have certain medical needs at the 
market (identified though literature research, reference competence groups, in-house 
knowledge). Our task is to meet customers’ needs with our functional spectrum of technology.” 
 
The strategy of Camurus AB is based on delivering those value propositions to the customers, 
which are relevant to a company’s available resources. As it is shown in the Table 5.2, the range 
of company’s offerings is quite large – from preclinical research in anti-diabetes medicines 
(which is considered to be a niche market) to registered dental gel against paradontitis (which 
goes to mass market). As the CEO denoted: 
 
“We do not have a strategic preference on niche products, though there are some advantages of 
niche markets: smaller scope, fewer products, fewer players. But for niche products you can do 
very limited clinical trials. If to go into niche market – the company would never take a product 
longer than phase II. We don’t exclude the possibility to go there – if we see that technology and 
capacities can fulfill large medical need, we’ll go there.” 
 
An important part of the company’s business model is the drug-delivery technologies. Aimed at 
“better treatment outcomes while improving convenience, compliance and quality of life”, drug-
delivery technologies produced by Camurus provide support for the drug production (Camurus 
AB, 2011). The pharmaceutical companies producing medicines that have some limitations or 
inconveniences in use by patients are the main consumers of the Camurus’s drug-delivery 
technologies. 
5.3. QPharma 
QPharma started its history in 1975 when pharmaceutical company Ferrosan constructed a plant 
in Malmö. Almost 10 years later Ferrosan and Leo merged and were acquired by Pharmacia 
which was interested in getting more production capacities in Skåne in 1986. In 1995 Ferring 
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acquired the plant from Pharmacia (now Pfizer). QPharma was formed in 1999 as a contract 
manufacturing company and in 2000 was acquired by Nordic Group BV. QPharma is still 
producing some of the Pfizer’s and Ferring’s products by contract (QPharma, 2011). 
 
Nowadays QPharma focuses not only on contract manufacturing but on contract development 
and analytical services. Contract manufacturing includes manufacturing of a range of solid 
dosage products and polymeric controlled-release delivery systems; as well as customized 
packaging and source high-quality packaging materials that comply with all regulatory 
requirements (QPharma, 2011). QPharma is experienced in different kinds of technology 
transfers, which broadens the spectrum of possible ways of cooperation with the company. 
Contract development in QPharma covers contract R&D projects starting from preclinical 
research to commercialization. Analytical service includes lab testing, project management etc. 
 
CEO of QPharma Kenneth Stokholm give the following description of a company’s business 
model: 
“Our business model is similar to many contract manufacturers. It doesn’t contain any basic 
research, we don’t do anything for ourselves – there are always customers with contracts 
working with us. If we are given a development task, we are paid for it. We don’t have a major 
risk of investing money in a product which will not succeed. If the product is not successful on 
the further preclinical or clinical trials QPharma is still paid for their part of the development 
work. The customer takes the all risks. If the trial is successful – it moves to commercial 
production – we are given the opportunity to produce for the customer as well. In that respect – 
we have a lower margin on our products but also a low risk The challenge lies in selecting the 
development projects that are most likely to succeed in clinical trials and proceed to commercial 
production. 
We are successful in what we do. Due to the growing development part we have 10 projects 
today in comparison with 1 project 5 years ago. That means that the growth of revenue from 5% 
5 years ago to 30% now. Some of the projects are moving into the commercial production – the 
model is working very well. In comparison with those contract manufacturing pharmaceutical 
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companies which chose to focus on manufacturing without development, this model is working 
better.” 
 
The basic products which QPharma produces are silicon based products which is the company’s 
competitive advantage, since very few pharmaceutical companies specialize on that delivery 
system. The company’s strategy of focusing on specialized production and “contract” services 
allows it to mitigate risks and to keep competitiveness at the market.  
 
Business models of both companies are constructed on the basis of Oswerwalder’s (2004) 
business model and Osterwalder and Pigneur (2009) business model canvas concept and 
analyzed in the further section. 
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6. Results and analysis 
The following chapter presents the empirical analyses of the data collected from the two 
pharmaceutical companies. The business models of Camurus AB and QPharma are constructed 
on the basis of the business model theoretical framework by Oswerwalder’s (2004) business 
model. Further on, business models of the companies above are compared with the theoretical 
blockbuster business model constructed and presented in Chapter 3. 
The data collected during the in-depth interviews with Camurus AB and QPharma are analyzed 
according to the business model concept by Osterwald and Pigneur (2004) presented in Chapter 
2. The four pillars of the business model  - Value Proposition, Customer Interface, Infrastructure 
Management Interface and Finance – contain information about the companies and are further 
decomposed into business model’s blocks. Each block is analyzed according to the all 
parameters discussed in the section 2.2 of the Chapter 2.  
 
Figures 6.1 and 6.2 present synthesized business models of Camurus AB and QPharma. 
Reflecting these projections on the definition of the business model presented in Chapter 2, 
Figures 3.2-3.3 and 6.1-6.2 present the way how companies convert their inputs (technological 
characteristics and potentials built on key activities, key resources and key partners) into 
economic outputs by means of value proposition (product or service offering) creation and 
delivery through target customer segments, customer relations and markets as a distribution 
channel. 
 
Both companies are using alternative to the blockbuster business model – Camurus is a small 
pharmaceutical company with focus on R&D, while QPharma is a middle-sized contract 
development and manufacturing company. Being similar in some general patterns like 
participation in networks, customer relations and distribution channels, both companies have 
their specific distinctive features. 
 
To start with, the business models of both companies have core differences in their offerings 
and value proposition in general. Value proposition of Camurus AB consist of two major 
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offerings: drug delivery technologies and R&D on different phases in the pipeline. The drug 
delivery technologies are developed in-house and deliver value to the customer through technical 
superiority in comparison with competitive offerings. 
 
The drug delivery technology offering creates value to the customer through its use and efforts 
reduction – these technologies are used in combination with other drugs’ ingredients for creation 
of the safer and more convenient-in-use medicines. The value level of the offering is created 
through innovation; offering’s price level is built on the basis of the market price.   
 
Both companies have an R&D offering. The main difference between these offerings lies in the 
way the companies identify and create them. Camurus AB is either independently trying to 
identify customers’ needs and to start a R&D process till the certain exit point (depending on 
investments), or is working on partner projects. Camurus AB doesn’t focus on any specific group 
of products for the creation of the new offerings – a combination of customers’ needs and 
available technology determines the offering. In contrast, QPharma’s offering is directly 
dependent on the contract with the customer – the value is delivered through R&D progress 
delivery at a certain development phase. QPharma doesn’t have any in-house R&D projects, the 
all projects are “ordered” by other companies. In both cases value of the R&D offering is created 
through the use of the proposition (further development or commercialization) and at the market 
price. Value is delivered differently: in case of Camurus AB – through innovation; in case of 
QPharma – either through innovation, or through innovative imitation, or though me-too projects 
(depending on the contract). 
 
Apart from the R&D offering, QPharma’s value proposition comprises 2 more offerings: 
contract manufacturing offering and analytical service. Firstly, contract manufacturing offering 
creates value through reduction in efforts – value for the customer is created at the moment when 
the contract company signs an agreement with QPharma about the outsourcing of drug 
production. Secondly, value is created through the use of the offering - older products have lower 
production cost, because of the continuous improvement of the production process, which leads 
to the lower price for the customer. 
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Figure 5.1. Camurus AB business model (conceptualized on the basis of business model concept by Osterwalder (2004) and business 
model canvas by Osterwalder and Pigneur (2009) 
Offer Infrastructure Customer 
Finance 
 
 
On technology side – 
about 10 
pharmaceutical 
partners (drug-delivery 
technologies are 
combined with 
partner’s drugs and 
delivered to the 
market) 
On educational side – 
Institute of 
Biotechnology in 
Vilnius, Lithuania;  
Lunds University; 
Oxford University  
 
 
 
Intangible: 
Intellectual capital;  
 
Human resources 
(27 employees + 
contractors);  
 
Tangible: available 
technology 
 
 
 
R&D on different 
phases 
 
 
 
 
Ways of supporting 
relationship: 
retention, acquisition; 
Mechanisms: 
personalization, trust 
 
 
 
Indirect: 95% 
Direct (with Episil): 
5% 
 
B2B customers:  
 
Big pharma – 70% 
Small pharma –30% 
 
B2C customers (with 
Episil) 
 
Drug-delivery technologies 
(developed in-house): 
 
Reasoning: use, effort 
Value level: innovation 
Price level: market price 
Life cycle: use 
 
R&D projects: 5 in-house projects 
(different phases), 2 out-licensed 
projects, range of partner projects: 
 
Reasoning: use 
Value level: innovation 
Price level: market 
Life cycle: use 
 
Emphasis on technical superiority 
of our solutions and competence 
 
R&D – 80% of turnover 
 
R&D collaboration – number one 
Out-licensing – number two 
Direct sales – number three 
Value-driven 
Partner network Key activities 
Key Resources 
Value proposition Customer 
Relationship 
 
Distribution 
Channel 
Customer Segments 
Cost Structure Revenue Stream 
Tetyana Syrovatka                                                              MSc in Economic growth, innovation and spatial dynamics 
54 
 
Figure 5.2. QPharma business model (conceptualized on the basis of business model concept by Osterwalder (2004) and business 
model canvas by Osterwalder and Pigneur (2009)
Offer Infrastructure Customer 
Finance 
On non-governmental 
side – Population 
council (joint projects 
on vaginal ring 
development for 
dveloping countries); 
International  
Partnership for 
Microbicides (IPM) –
(joint project on HIV 
prevention) 
 
On commercial side: 
Johnson&Johnson, 
Ferrosan, Ferring etc 
 
 
 
Human resources 
(115 employees);  
 
Tangible: available 
technology 
 
 
 
Contract 
manufacturing:  65% 
 
Contract 
development: 30% 
 
Analytical service: 
5% 
 
 
Ways of supporting 
relationship: retention, 
acquisition; 
Mechanisms: 
personalization, trust 
  
 
 
Direct and indirect 
both (dependently from 
the contract conditions) 
 
 
B2B or B2C customers 
dependently on the 
contract; 
 
Shift to more to the 
niche markets // areas 
 
 
 
 
Contract manufacturing: 
Reasoning: effort 
Value level: excellence in quality 
Price level: market 
Life cycle: customization 
 
Contract development: 
Reasoning: effort, use 
Value level: innovation, innovative 
imitation 
Price level: market 
Life cycle: use 
 
Analytical service: 
Reasoning: effort, use 
Value level: me-too value, innovation 
Price level: market 
Life cycle: use 
 
2 types of deliverables: solid dosage 
products and polymeric controlled-
release systems. 
 
Manufacturing – the biggest part of the cost structure 
 
 
Contract manufacturing:  65% 
Contract development: 30% 
Analytical service: 5% 
Value-driven 
Partner network Key activities 
Key Resources 
Value proposition Customer 
Relationship 
 
Distribution Channel 
Customer 
Segments 
Cost Structure Revenue Stream 
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In addition, new products deliver value in terms of delivery systems (convenience of use for the 
customer) – the same medical need but has more convenient solution for the patient, better side 
effect profile, lower dose of medicine. In case of manufacturing value is delivered to the 
customer though excellence of execution at a market price. In case of analytical services value is 
created either through me-too services (use of standardized techniques) or through innovation 
(innovative analytical testing) at a market price.  
 
Both companies have a clearly defined value proposition which is diversified into several 
offerings. Comparing with the blockbuster model (Figure 3.2), QPharma and Camurus reduced 
their risk and level of uncertainty through a diversified value proposition and focus on a certain 
part of pipeline. 
 
Customer interface pillar of the companies’ business models have more similarities than 
differences. The main difference is that QPharma is trying to shift to the niche markets, and 
Camurus AB don’t have any preferences concerning the niche or mass market. Both companies 
aim their value proposition at the B2B segment of customers. In case of QPharma – B2B 
customers comprise other pharmaceutical companies working with QPharma on contract 
conditions. If the contract assumes that QPharma is taking the product through the all pipeline to 
commercialization, QPharma will deliver the value proposition to B2C segment of customers – 
directly to the drugs’ customers at the market. In case of Camurus AB – 95% of the targeted 
customers are B2B customers (of which 70% - Big Pharma and 30% - Small Pharma) and 5% - 
B2C customers (consumers of Episil). Respectively, both companies are using indirect 
distribution channels to the larger extend than direct. Another similarity is that both companies 
use mainly retention for supporting relations with their customers and, to the smaller extend, - 
acquisition. The main mechanisms used by the companies are personalization and trust. 
Acquisition of the new customers is done through personal meetings of potential customers at the 
different conferences and is based on personalized contacts. 
 
Comparing the customer interface pillar of the blockbuster business model with alternative 
business models above it is necessary to point out the major differences between them. First, 
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blockbuster model doesn’t have clearly formed customer segment (it is very vast), whereas 
QPharma and Camurus AB can configure the major group of their customer and focus on their 
retention. Second, as a consequence of the previous argument, blockbuster companies have to 
spend huge costs on marketing of their production. Camurus AB and QPharma promote their 
value proposition through personalized contacts, which is impossible in case of the blockbuster 
model.  
 
The infrastructure management pillar in both models is built on the core capacities of the 
companie. The key resources of Camurus AB are intangible (intellectual capital: out-licensing), 
tangible (available technological capacities) and human (27 employees plus constructors for 
consultancy, organization for preclinical testing etc). A combination of key resources with 
customers’ need determine the company’s value proposition at the market. Talking in Wallin’s 
(2000) terms, Camurus AB possesses generative capabilities, e.g. innovation and customer-
interaction capabilities. The value configuration of Camurus AB consists mainly of R&D on 
different phases. 
 
As for the QPharma, tangible (available technology, plants) and human resources are core for the 
value proposition delivery. From Wallin’s (2000) perspective, the core capabilities of QPharma 
are generative (more execution and less – innovation) and customer interaction capabilities. 
Correspondingly, key activities of the company are: contract manufacturing (65%) contract 
development (30%) and analytical service (5%). According to the QPharma’s CEO, new 
manufacturing unit will be constructed next year – the company is investing in enlargement of 
the core capabilities block. 
 
In contrast to QPharma and Camurus AB, who make an emphasize on their key resources 
utilization and building competitive advantage on the basis of it, the blockbuster business model 
keeps the whole production pipeline in-house. QPharma and Camurus AB are exactly those kind 
of companies which blockbuster company should cooperate with. Through R&D or drug 
manufacturing outsourcing to smaller companies like Camurus AB or QPharma, the blockbuster 
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company will mitigate the risks of drug development failure and decrease the costs for non-core 
company activities. 
 
The last block of the infrastructure management pillar is partnership networks. Both companies 
are participating in business, non-governmental or educational networks with the same 
incentives: a partnership for customer acquisition and knowledge sharing. From the commercial 
side, QPharma cooperates with companies primarily from Europe and the USA (Pfizer, Ferring, 
Johnson&Johnson, etc). This is a partnership for customer acquisition and risk mitigation. 
Besides that, QPharma cooperates with non-governmental institutions for the purpose of the 
development of accessible medicines for developing countries: with the Population Council on 
development of contraception vaginal ring and with the International Partnership for 
Microbicides (IPM) on development of medicines against HIV. Such kind of partnership can be 
classified as a partnership for knowledge sharing according to the theoretical framework used for 
the purpose of this research.  
 
Camurus AB has around ten partners at the technology side. Besides that, Camurus AB 
participates in networks with educational institutions – the Institute of Biotechnology in Vilnius, 
Lithuania;  Lunds University in Sweden; Oxford University in England. These are a partnerships 
for customer acquisition and partnerships to acquire knowledge respectively. 
 
One of the sharpest differences between the blockbuster business model and alternative ones lies 
in the partnership block. In contrast to the partnership blocks described above, the blockbuster 
companies doesn’t participate in any partnership networks.  
 
Concerning financial aspects, QPharma and Camurus AB have a similar structure of cost and 
revenue stream blocks. The biggest part of the cost structure at QPharma is manufacturing and at 
Camurus AB – R&D. Naturally, companies invest the most in their core capabilities. In 
comparison, the cost structure of the blockbuster pharmaceutical company is much more 
complicated because it has to invest not only in core activities, but also in maintenance of the 
whole in-house development processes. 
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Revenue streams at QPharma and Camurus AB are divided respectively to the value 
proposition’s offerings. The biggest revenue sources for Camurus AB are, respectively, R&D 
collaboration, out-licensing and direct sales. Therefore, two revenue stream types can be 
distinguished: selling (R&D and direct sales) and out-licensing. For the R&D and out-licensing 
differential pricing is used (product feature dependent and value based) and for the direct sales – 
a market pricing mechanism is used. The revenue streams at QPharma are divided 65%/30%/5% 
between contract manufacturing, contract development and analytical services. The stream type 
is selling – all the above services and activities are sold to the customer. The pricing mechanism 
used is differential pricing.  
 
The blockbuster model has revenue streams from the high volumes of blockbuster drug sales 
and, sometimes, from licensing. The main challenge for the blockbuster company is that the 
blockbuster drug will not get to the final stage of development and will not be launched. That 
will mean huge losses for the company. Comparing to the blockbuster business model, QPharma 
and Camurus AB have more stable revenue streams which are less risk sensitive. 
 
Both companies are value driven. QPharma presents its competitive advantage as a combination 
of reliable supply, delivery in time, high quality and unique capacities of combining silicon 
production. Camurus AB positions itself also as a company which is aimed at quality delivery 
more than at the cost reduction. The blockbuster pharmaceutical companies try to be both – 
value- and cost-driven. From the one side, it should deliver high quality with the blockbuster 
drug, but from the other side – affordable for the wide spectrum of customers. 
 
As it was illustrated in the Chapter above, alternative business models emerging at the 
pharmaceutical industry today are much more flexible and adapted to the market changes and 
shifts than the blockbuster business model. 
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7. Conclusions and discussion  
The following chapter holds a discussion on the findings of the research presented in the paper. 
A short analytical summary about the business model concept used for the research is made. 
Furthermore, the possibilities of further research, as well as practical implications of this study 
are developed and reflected on. 
7.1. Summary of the findings 
The study presented above sheds light on the major shifts in the business models in the 
pharmaceutical industry. The combination of the theoretical approach with in-depth interviewing 
allowed to describe the issue of the business model’s shift in details and to compare theoretically 
constructed models with the business models constructed for the real companies. 
 
The defragmented business model in Chapter 3 projected the theoretical conceptualization of the 
new alternative business model in the pharmaceutical industry. In relation to further research, it 
is also reflecting expected findings of the empirical study. The results of the empirical analysis 
reported in Chapter 6 supports the results of theoretical analysis presented in Chapter 3 and 
illustrate the major changes in the business model in the pharmaceutical industry in relation to its 
theoretical conceptualization. Thus, the answer to the researched questions “What is the old 
business model in pharmaceutical industry?”, “What is the new business model in 
pharmaceutical industry?”, “What are the major difference between old blockbuster business 
model and new alternative model?” are illustrated in Table 7.1. 
 
Table 7.1 presents a summary of expected empirical results (which are embodied in the 
theoretically constructed disintegrated model) in comparison with real findings from the in-depth 
interviews with two pharmaceutical companies. A parallel comparison with the old blockbuster 
model gives a summary of the major shifts in business models in the pharmaceutical industry. 
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No Business model 
element 
Expected results: 
Theoretically constructed 
new defragmented 
business model 
Actual findings: 
Real business models of 
two pharmaceutical 
companies 
Comparison: 
Theoretically 
constructed old 
blockbuster business 
model 
1. Value 
proposition 
Based on the particular 
part of the drug 
development pipeline 
(R&D; drug development 
on the phases 1-2; drug 
manufacturing etc); 
including satellite services 
into the real product 
proposition 
Based on the certain part 
of pipeline; 
diversification of the 
value proposition into 
several 
products/services 
Blockbuster drug   
2. Target customer 
(customer 
segment) 
Niche markets or 
specification on certain 
area (e.g. cardio-vascular 
diseases) 
Niche market or clearly 
formed customer 
segment based on 
emerging customer 
needs 
Mass markets – wide 
range of customers 
 
3. Customer 
relationship 
More personalized 
relations with customers 
Personalized contacts Mass marketing of the 
blockbuster drug; 
no personal contacts 
with the customers 
4. Distribution 
channel 
Direct/indirect – 
depending on the value 
proposition 
Direct/indirect– 
depending on the value 
proposition 
Direct, since the only 
value proposition is a 
blockbuster drug 
5. Key activities Based on core 
capabilities; 
investments saved on 
promotion into the key 
activities 
and core capabilities 
 
Based on core 
capabilities utilization; 
investments into core 
capabilities 
 
All-in-house 
production; 
no emphasis on the 
key activities  
6. Key resources Focus on its core 
capabilities, e.g. 
capabilities on which this 
company can build 
competitive advantage; 
outsourcing of those 
capabilities which are not 
core and insourcing of 
those capabilities which 
are needed for value 
proposition delivery 
Focus on its core 
capabilities  
All-in-house 
resources; 
no division in core and 
not-core capabilities 
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7. Partnership 
network 
Risks and uncertainty 
reduction through 
participation in the 
networks 
Participation in the 
business, knowledge 
networks; 
networking for risk 
reduction 
No participation in any 
partnership networks.  
 
8. Cost structure Related to its core 
capabilities utilization 
Related to its core 
capabilities utilization 
Related to the whole 
in-house development 
processes 
9. Revenue stream Based on the core 
activities and kind of 
value proposition 
Divided respectively to 
the value proposition’s 
offerings. 
Based on the high 
volumes of 
blockbuster drug sales 
and, sometimes, from 
licensing 
Table 7.1. Comparison between empirically built business model, theoretical 
disintegrated and blockbuster business models. 
As it is illustrated in the Table 7.1, the theoretical conceptualization of the alternative business 
model, i.e. the new defragmented business model, is congruent with the business models 
constructed on the basis of empirical research. Though the empirical research cannot be 
generalized on the whole region, because of the in-depth interviews’ limitation, it gives a deeper 
insight into their analysis. The results reported here confirm the value of the business model 
concept and, therefore, that the conceptualization of the alternative defragmented business model 
is coherent with the pharmaceutical companies which participated in the research. 
 
Analyzing the differences between old and new business models in the pharmaceutical industry, 
the major shifts in the business models can be summarized. The most fundamental shift is the 
change from the obsolete blockbuster business model aimed at the all-in-house pipeline 
production of the single blockbuster drug for the mass market to the alternative defragmented 
business model which specifies on the certain part of the production pipeline and targets its 
offers at the niche markets. To summarize, on the basis of this study the main shifts in the 
business models in the pharmaceutical industry can be generalized as follows: 
 From large scale to narrow focus; 
 From mass market to niche market; 
 From mass marketing to personalized customer relations; 
 From all-in-house to outsourcing; 
 From profit-alone to profit together; 
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 From high risks to risk mitigation. 
 
Since the present study is built around the business model concept, the weaknesses and strength 
of the selected approach by Osterwalder and Pigneur (2004) are discussed in the following sub 
section. 
7.2. The business model concept 
For the purpose of this study the business model framework developed by Osterwalder and 
Pigneur (2004) was used. Since the model concept above pursues the goal to describe business 
models in general - independently from the industry or sector - it may need some adjustments 
according to the researched area.  
 
A strong point of the model is its coherency and details-orientation. A clear decomposition into 
four interrelated pillars allows to draw a full picture of how the company functions. Further 
deconstruction into smaller blocks which, in turn, consist of a range of precise and detailed 
elements, is a useful tool for the deep understanding of the company’s business structure. The 
model is easy to follow and to understand because of the consistent explanation of each sub-
element made by the authors. 
 
As a consequence of specificity of the researched area, i.e. the pharmaceutical industry, some 
elements of the business mode can be adjusted for the improvements in the further research on 
this paper. For example, some attributes of the value proposition block can be modified 
according to the pharmaceutical industry, e.g. reasoning. The types of reasoning attribute 
suggested by Osterwalder (2004) include use, risk and effort. Since pharmaceutical companies 
often produce non-tangible goods, it makes it difficult to explain whether these goods are 
valuable to the customer because of their use, risk reduction or effort reduction. The possible 
modification in classification can be made by including such characteristics as “research and 
development” – if the company focus on R&D offers and “production” – if the company 
specifies on the drug manufacturing. The attributes “risk reduction” and “effort reduction” can be 
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eliminated, since the all pharmaceutical activities are aimed at the risk and effort reduction (to 
create safer medicines and to make the process of taking medicines easier for the patients). 
 
To conclude, the business model concept used in the study is a good tool for the description of 
the company’s business model, but it may be adjusted with small specifications according to the 
area it is applied to. 
7.3. Further research and practical implications  
This study both corroborates previous research in business models’ shifts and could be the 
starting point for future research in the pharmaceutical industry. Though the research presents a 
number of limitations that make it difficult to generalize from these findings, it offer new 
insights and supports previous findings about the shift in the business models. 
 
A practical implication of this study is that it can be used by pharmaceutical companies as a 
guideline for business modeling. The theoretical framework of this study can be used as a 
manual for the company willing to construct its business model. Besides, the hints about the 
major shifts in the business models in the pharmaceutical industry gives companies a possibility 
to evaluate their business models in comparison with theoretically constructed models. 
 
For the purpose of the further research it may be interesting to make a survey among all the 
pharmaceutical companies in the Skåne region. The survey should be based on the business 
model concept described in this study and adjusted specifically to the pharmaceutical industry. 
Data on the business models of the pharmaceutical companies in the whole region will allow 
making more aggregated conclusions and proving theoretical models presented in this research. 
 
Conclusions made on the survey basis in addition to this study will illustrate the whole picture of 
the pharmaceutical industry in the region, which will make it possible to analyze existing trends 
more carefully and to implement some corrections into the policy towards pharmaceutical 
industry development. Besides, the survey analysis will help companies to understand more 
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precisely what the competitive situation in the region is and what the possible areas for 
improvements in their business models are.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Tetyana Syrovatka                                                              MSc in Economic growth, innovation and spatial dynamics 
65 
 
List of references 
Afuah, A. and C. Tucci (2001). Internet Business Models and Strategies. Boston, McGraw Hill // 
Afuah, A. and C. Tucci (2003). Internet Business Models and Strategies. Boston, McGraw Hill 
Amit, R. and C. Zott (2001). Value creation in e-business. Strategic Management Journal 22(6-
7): 493-520 
Archibugi, D. and S. Iammarino (2002). The globalization of technological innovation: 
definition and evidence. Review of International Political Economy 9(1): 98-122 
Barney, J., Wright, M., & Ketchen, D. J. J. (2001). The resource based view of the firm: Ten 
years after 1991. Journal of Management, 27(6), 625-641. Elsevier Science Inc. 
Bátiz-Lazo, B., & Holland, S. (2001). Strategy and structure of the pharmaceutical industry. The 
Open University 
Berg, B. L. (2009). Qualitative research methods for the social sciences. Boston: Allyn & 
Bacon. 
Betz, F. (2002). Strategic business models. Portland International Conference on Management of 
Engineering and Technology  
Britannica, E. (2009). Encyclopædia Britannica Online. Available at 
<http://www.britannica.com> 
Camurus AB (2011). Available at <http://www.camurus.com/> 
Chesbrough, H. and R. S. Rosenbloom (2000). The Role of the Business Model in capturing 
value from Innovation: Evidence from XEROX Corporation’s Technology Spinoff Companies. 
Boston, Massachusetts, Harvard Business School. 
Chesbrough, H. W. (2007). Business model innovation: it’s not just about technology anymore. 
Strategy Leadership, 35(6), 12-17.  
Chesbrough, H. W. (2007). Why companies should have open business models. MIT Sloan 
Management Review 
Tetyana Syrovatka                                                              MSc in Economic growth, innovation and spatial dynamics 
66 
 
Chesbrough, H. W. (2010). Business Model Innovation: Opportunities and Barriers. Long Range 
Planning, 43(2-3), 354-363 
Center for Drug Evaluation and Research,U.S. (2009). Generic Drugs. Food and Drug 
Administration 
Datamonitor. (2010). Pharmaceutical Key Trends 2010. Available at < 
http://www.datamonitor.com/store/product/pharmaceutical_key_trends_2010_the_patent_cliff_d
ominates_but_growth_opportunities_remain?productid=DMHC2599> 
Denzin, N., & Lincoln, Y. (2000). Handbook of qualitative research. Thousand Oaks, CA: Sage. 
Dyer, J. H., & Singh, H. (1998). The relational view: Cooperative strategy and sources of 
interorganizational competitive advantage. Academy of Management Review, 23(4), 660-679.  
Eneroth, K. (2001). Knowledge webs and generative relations: A network approach to 
developing competencies. European Management Journal, 19(2), p.174-182. 
Gilbert, J., Henske, P., & Singh, A. (2003). Rebuilding Big Pharma ’ s Business Model. In Vivo, 
21(10), 1-10. 
Gloor, P.A. & Cooper, S.M. (2007). The New Principles of a Swarm Business. MIT Sloan 
Management Review, 48(3), p.81-84.  
Hamel, G. (2001). Leading the revolution. Business, 35, 354-355. Harvard Business School 
Press.  
IMS report (2011). The Global Use of Medicines: Outlook Through 2015. Available at < 
http://www.imshealth.com/deployedfiles/imshealth/Global/Content/IMS%20Institute/Static%20
File/Global_Use_of_Medicines_Report.pdf > 
IMS Health Midas (2010). Available at 
<http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/
Top_20_Global_Companies.pdf> 
Tetyana Syrovatka                                                              MSc in Economic growth, innovation and spatial dynamics 
67 
 
Invest In Skåne (2011). Available at <http://invest.Skåne.com/content/life-science> 
Jarillo, J. C. (1995). Strategic networks. Oxford: Butterworth-Heinemann 
Johnson M.W., Christensen C.M., Kagermann H. (2008). Reinventing your business model. 
Harvard Business review 
Kim, W.C. & Mauborgne, R. (1997). Value Innovation : The Strategic Logic of High Growth. 
Harvard Business Review, 75(1), p.103-112.  
Linder, J. & Cantrell, S. (2000). Changing Business Models: Surveying the Landscape. Business, 
p.1–13.  
Litinski, V. (2010). Business model innovation in pharma and medtech: Watching the birth of a 
new salesman. Available at <http://www.marsdd.com/2010/12/02/business-model-innovation-in-
pharma-and-medtech-watching-the-birth-of-a-new-salesman> 
Magretta, J. (2002). Why Business Models Matter. Harvard Business Review 80(5): 86-92. 
Mercer commentary (Mercer Management Consulting) (2001). Where are the next profit zones 
in pharmaceuticals? The blockbuster model will begin to yield winners and losers. Available at < 
http://www.hanovermatrix.com/pages/matrix/pdf/pharmcomment.pdf > 
MediconValley (2011). Available at 
<http://www.mediconvalley.com/content/us3/generel_pages/life_science_organizations> 
Morris, M., Schindehutte, M., & Allen, J. (2005). The entrepreneur's business model: toward a 
unified perspective. Journal of Business Research, 58(6), 726-735.  
Osterwalder, A. (2004). The Business Model Ontology - A Proposition In A Design Science 
Approach, University of Lausanne. Available at 
<http://www.hec.unil.ch/aosterwa/PhD/Osterwalder_PhD_BM_Ontology.pdf> 
Osterwalder, A. (2005). Aging business models in pharmaceutical industry. Available at 
<http://www.businessmodelalchemist.com/2005/06/aging-business-models-in.html> 
Tetyana Syrovatka                                                              MSc in Economic growth, innovation and spatial dynamics 
68 
 
Osterwalder A., Lagha S.B., Pigneur Y. (2002). An Ontology for Developing e-Business Models.  
Osterwalder, A., Pigneur, Y., & Tucci, C. L. (2005). Clarifying business models: Origins, 
present, and future of the concept. Communications of the Association for InformationSystems, 
16(1), 1-25.  
Osterwalder, A., & Pigneur, Y. (2009). Business Model Generation. self published. John Wiley 
& Sons. Available at < businessmodelgeneration.com>  
Petrovic, O., C. Kittl, et al. (2001). Developing Business Models for eBusiness. International 
Conference on Electronic Commerce 2001, Vienna 
Porter, M. E. (1985). Competitive Advantage. (, Eds.)Management Information Systems, 19, 
487-505. Free Press. 
Prahalad, C.K. & Hammond, A. (2002). Serving the world’s poor, profitably. Harvard Business 
Review, 80(9), p.48-57, 124 
Prahalad, C.K. & Ramaswamy, V. (2003). The new frontier of experience innovation. MIT Sloan 
Management Review 
PriceWaterhouseCooper (2009). Pharma 2020: Challenging Business models. Available at < 
http://www.pwc.com/nl/nl/publicaties/pharma-2020-challenging-business-models.jhtml > 
Rappa M (2002) Business models on the web. Available at 
<http://digitalenterprise.org/models/models.html 
Seget, S. (2010). Pharmaceutical Market Trends, 2010-2014. Key market forecasts and growth 
opportunities. Urch Publishing. 
Shafer S.M., Smith H.J., Linder J.C. (2005). The power of business models. Business Horizonts: 
48, 199-207 
Surya C. (n.d.). Evolving operational decision models in the pharmaceutical industry. Available 
at <http://www.slideshare.net/chitrasp/evolving-operational-business-model-in-pharmaceutical-
industry> 
Tetyana Syrovatka                                                              MSc in Economic growth, innovation and spatial dynamics 
69 
 
Wallin J. (2000). Operationalizing Competences. The fifth International Conference on 
Competence-Based Management: Helsinki, Finland 
Weill, P. and M. R. Vitale (2001). Place to space: Migrating to eBusiness Models. Boston, 
Harvard Business School Press. 
Wolthuis, N. (2010). Value Creation in Innovation Networks: A Business Model Approach. 
Available at <http://alexandria.tue.nl/extra1/afstversl/tm/Wolthuis%202010.pdf> 
QPharma (2011). Available at <http://www.qpharma.se/about_facts.html> 
 
 
 
 
 
 
 
 
